Puregene dna blood kit

Eighty-four individuals were sequenced in this study. Forty-eight individuals with hypertriglyceridemia (HTG) had plasma triglyceride levels greater than 10 mmol/L with no genetic explanation. Specifically, the subjects do not have CNVs or deleterious variants in triglyceride-associated genes: LPL, APOC2, APOA5, LMF1, GPIHBP1, GPD1 and GALNT2. The other 36 individuals were controls with triglyceride levels less than 2 mmol/L. The project was approved by the human ethics review board of Western University (#07920E). DNA was isolated at the Blackburn Cardiovascular Genetics Laboratory from 4 mL of blood using the Puregene® DNA Blood Kit (Gentra Systems, Qiagen Inc., Mississauga, ON, Canada). DNA quantities and quality were measured using a NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and samples diluted to 30 ng/μL. Libraries containing 12 samples each were prepared at the London Regional Genomics Centre as described in the Nextera Rapid Capture Enrichment protocol and then sequenced on an Illumina MiSeq (Illumina, San Diego, CA, USA). The data was output as FASTQ files containing the sequencing reads with corresponding quality score determined by the sequencer for each nucleotide. The raw sequencing reads were deposited as FASTQ files and can be found at the European Nucleotide Archive under accession number PRJEB32805.

Genomic DNA is extracted from blood (95% of samples) using the Puregene® DNA Blood Kit (Gentra Systems, Qiagen Inc., Mississauga ON, Canada) (Cat No. 158389) or saliva (5% of samples) using the Oragene DNA kit (DNA Genotek Inc., Ottawa ON, Canada; Cat No. OG-500).